What is Zacks Research’s Estimate for Alkermes Q1 Earnings?

Alkermes plc (NASDAQ:ALKS) – Equities research analysts at Zacks Research lifted their Q1 2025 earnings per share estimates for Alkermes in a research note issued on Wednesday, March 5th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.29 per share for the quarter, up from their prior forecast of $0.22. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes’ Q2 2025 earnings at $0.35 EPS, Q3 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.42 EPS, FY2025 earnings at $1.35 EPS, Q1 2026 earnings at $0.25 EPS, Q2 2026 earnings at $0.34 EPS, Q3 2026 earnings at $0.24 EPS, Q4 2026 earnings at $0.36 EPS and FY2026 earnings at $1.19 EPS.

Other equities research analysts also recently issued reports about the company. Deutsche Bank Aktiengesellschaft initiated coverage on Alkermes in a report on Tuesday, February 11th. They set a “buy” rating and a $40.00 price objective on the stock. StockNews.com upgraded shares of Alkermes from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 13th. HC Wainwright reiterated a “neutral” rating and set a $46.00 price objective on shares of Alkermes in a research note on Thursday, February 13th. Mizuho raised their price objective on shares of Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, UBS Group upgraded shares of Alkermes from a “sell” rating to a “neutral” rating and upped their target price for the company from $21.00 to $38.00 in a research note on Tuesday, March 4th. Three equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.33.

Alkermes Stock Performance

NASDAQ:ALKS opened at $34.35 on Friday. The stock has a market cap of $5.59 billion, a price-to-earnings ratio of 15.83, a price-to-earnings-growth ratio of 2.20 and a beta of 0.62. Alkermes has a one year low of $22.90 and a one year high of $36.45. The business’s 50-day simple moving average is $31.85 and its 200 day simple moving average is $29.64.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

Insider Transactions at Alkermes

In other Alkermes news, Director Cato T. Laurencin sold 2,691 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the sale, the director now directly owns 23,013 shares in the company, valued at $732,964.05. This represents a 10.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Craig C. Hopkinson sold 144,419 shares of Alkermes stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the transaction, the executive vice president now owns 57,875 shares in the company, valued at approximately $2,056,298.75. This trade represents a 71.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 309,179 shares of company stock valued at $10,412,450. 4.89% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Centiva Capital LP acquired a new stake in Alkermes in the 3rd quarter valued at about $367,000. Natixis Advisors LLC raised its holdings in shares of Alkermes by 190.3% in the 3rd quarter. Natixis Advisors LLC now owns 36,490 shares of the company’s stock worth $1,021,000 after purchasing an additional 23,921 shares in the last quarter. Sanctuary Advisors LLC lifted its stake in Alkermes by 254.5% during the third quarter. Sanctuary Advisors LLC now owns 32,791 shares of the company’s stock valued at $944,000 after purchasing an additional 23,541 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Alkermes by 74.7% during the third quarter. BNP Paribas Financial Markets now owns 149,493 shares of the company’s stock worth $4,184,000 after buying an additional 63,939 shares in the last quarter. Finally, Barclays PLC boosted its holdings in Alkermes by 108.8% during the third quarter. Barclays PLC now owns 423,931 shares of the company’s stock worth $11,867,000 after buying an additional 220,893 shares in the last quarter. Institutional investors own 95.21% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.